Engineered Toll-like Receptor Nanoagonist Binding to Extracellular Matrix Elicits Safe and Robust Antitumor Immunity

The authors reported an improved CpG-based immunotherapy approach composed of a synthetic ECM-anchored DNA/peptide hybrid nanoagonist via a tailor designed DNA template that encodes tetramer CpG and additional short DNA moieties.